ingrezza post strong sale growth look past remaind
drive ingrezza sale outlook continu remain promis amid low diagnosi
rate td despit anticip soft due insur reset patient
navig thru medicar donut hole co receiv littl valuat
pipelin co activ build pipelin plan move sever
mid/lat stage trial
ingrezza made anoth record year patient number doubl
report ingrezza net sale q/q sale
y/i enter management mention insur re-author
gross-to-net discount inventori destock stock
headwind larg anticip given insur reset higher
discount occur past two year materi
headwind would lower refil rate could due extend cycl time
reauthor req ts adjust could occur vs howev
normal rest management continu emphas td market remain
penetr management also anticip second product launch w/ pot approv
opicapon april launch mid current expect slow launch
announc collabor xenon promis first-in-class
molecul featur potenc select block sodium channel
believ molecul hold promis treat rare devast type
pediatr epilepsi short name mechan action possibl support
efficaci rang seizur disord includ adult focal epilepsi file
ind mid start trial pt jan enter agreement
idorsia potent select oral activ calcium channel blocker
aim start trial pediatr epilepsi
pipelin updat ahead program management reiter plan present data
phii poc studi adult endo meet sf
present includ data two biomark acth across
cohort pivot global adult studi start mid vy-aadc gt prgm
gain clariti fda protocol amend underway
second pivot trial start
financi model updat report dilut ep
lower estimate con due incur ipr
expens associ voyag xenon deal management iss opex
guidanc reflect cost three pivot trial earli prgm
market cost opicapon launch result new pt
pleas see analyst certif import disclosur inform inform regard statu non-u analyst
page report
ingrezza approv tardiv dyskinesia peak
sale
orilissa approv endometriosi uterin
fibroid ww peak royalti
opicapon approv us file exist eu
data /canada peak sale risk-adj
better expect uptak ingrezza tardiv
dyskinesia back sale forc expans dtc
orilissa uterin fibroid de-risk posit trial
proof-of-concept data congenit adren
hyperplasia support initi registr trial
orilissa fail demonstr efficaci
uterin
fibroid and/or lower expect uptak
opicapon approv
fail demonstr efficaci congenit
expect continu growth ingrezza moderate-to-
sever mild tardiv dyskinesia ye
market share lead teva austedo
expect continu growth orilissa moderate-
ye
patient/physician awar
model us approv orilissa uterin fibroid
risk discount
model us approv opicapon
data updat phii adult
endo meet sf
mid updat registr program
adult follow discuss fda
apr fda decis opicapon
launch updat orilissa endometriosi
initi vy-aadc pivot trial
initi trial
initi trial rare
pleas see import disclosur inform page report
reach pt base discount rate termin growth rate
exhibit valu neurocrin ingrezza elagolix acquir asset opicapon
ingrezza believ domest probability-adjust sale achiev
tardiv dyskinesia td orilissa elagolix model launch
endometriosi expect launch uterin fibroid model
ex-u launch orilissa begin well believ orilissa achiev
domest probability-adjust sale risk adjust
endometriosi uterin fibroid respect assum risk-discount uterin
fibroid note product market partner model
tier royalti net sale tier royalti ex-u net sale
believ opicapon end-of-dos motor fluctuat parkinson diseas achiev
 /canada peak sale risk-adjust current includ
congenit adren hyperplasia valuat repres
addit upsid estim
compani data jefferi estim
clinic failur compani biotechnolog pharmaceut develop
treatment futur clinic failur lead delay approv possibl
discontinu program
regulatori failur fda could determin compani nda inadequ
could delay approv delay approv timelin could impact earn
commerci failur estim may reli success company/partn
receiv drug reimburs private/publ medic insur payer
financ risk may need rais addit fund support sg
activ current includ estim addit equiti rais howev
pleas see import disclosur inform page report
compani data jefferi estim
compani data jefferi estim
pleas see import disclosur inform page report
inc san diego-bas commercial-stag biopharmaceut compani focus develop
drug candid neurolog endocrin diseas neurocrin one market product ingrezza valbenazin
approv treatment tardiv dyskinesia compani second product orilissa elagolix partner
commerci approv treatment endometriosi pipelin includ product develop
parkinson diseas congenit adren hyperplasia rare/orphan endocrin diseas
pt dcf-base discount rate termin growth rate risk includ clinic regulatori commerci
biren amin certifi view express research report accur reflect person view subject
secur subject compani also certifi part compens directli indirectli relat
specif recommend view express research report
kelli shi phd certifi view express research report accur reflect person view subject
secur subject compani also certifi part compens directli indirectli relat
specif recommend view express research report
chang liu phd certifi view express research report accur reflect person view subject
secur subject compani also certifi part compens directli indirectli relat
specif recommend view express research report
jeet mukherje phd certifi view express research report accur reflect person view
subject secur subject compani also certifi part compens directli indirectli
relat specif recommend view express research report
case jefferi employe analyst respons coverag financi instrument discuss
report receiv compens base part overal perform firm includ invest bank incom seek
updat research appropri variou regul may prevent us asid certain industri report publish
period basi larg major report publish irregular interv appropri analyst judgement
articl articl
